LAS VEGAS, NV -- March 10, 2025 --
InvestorsHub NewsWire -- Avant Technologies Inc. (OTCQB:
AVAI) (“Avant” or the “Company”), and its partner, Ainnova
Tech, Inc., (Ainnova), a leading healthcare technology company
focused on revolutionizing early disease detection using artificial
intelligence (AI), today announced that Apollo Hospitals (Apollo)
and Ainnova have officially established a strategic collaboration
that marks a significant step forward in the integration of
artificial intelligence into disease detection and
prediction.
As part of this alliance, Ainnova
has secured an exclusive license for several advanced AI
algorithms, which have been rigorously validated with over 2.3
million data points and now form an integral part of Ainnova’s
Vision AI platform. These cutting-edge solutions enable the early
and precise detection of conditions, such as cardiovascular disease
(CVD), chronic kidney disease (CKD), liver fibrosis, type 2
Diabetes, and lung abnormalities in CT scans and X-rays, including
lung cancer.
Last month, Avant and Ainnova
signed a global development and licensing deal for Ai-Nova
Acquisition Corp. (AAC), the joint venture formed by both
companies. Given AAC’s territory now includes a global license to
develop and market Ainnova's technology portfolio, this partnership
with Apollo strengthens the joint venture’s efforts to advance AI
in Healthcare using Ainnova’s Vision AI platform and its
proprietary versatile retinal camera technology.
This week, most of these AI-driven
diagnostics will be available exclusively on the Vision AI platform
across the Americas, where the first commercial pilot programs are
set to launch in the coming weeks.
Notably, Brazil is already included
in the expansion roadmap, as the partnership has successfully met
the regulatory requirements set by ANVISA (Brazilian Health
Regulatory Agency). This milestone paves the way for
commercialization in a country with over 200-million
people.
The integration of these AI-powered
solutions aligns with efforts to enhance chronic disease management
by adding substantial value to patient care. By
providing a comprehensive preventive health assessment, these tools
aim to facilitate early referrals from primary care providers or
community health services, such as pharmacies, to specialized
medical professionals.
Apollo Hospitals is one of the
largest and most renowned private healthcare networks in Asia,
playing a leading role in transforming healthcare in India and
across Southeast Asia. With a robust presence that includes
hospitals, clinics, pharmacies, and diagnostic centers in the
region and beyond, Apollo remains at the forefront of medical
innovation.
With this alliance, Apollo
reaffirms its commitment to advancing global healthcare by
leveraging AI-powered solutions. Partnering with Ainnova in the
Americas underscores its dedication to driving innovation,
improving patient outcomes, and expanding access to
state-of-the-art medical technologies. Together, the two
organizations will continue to develop and deploy AI-driven
healthcare solutions with additional innovations set to be
introduced in the near future.
About Ainnova Tech,
Inc.
Ainnova is a Nevada-based
healthtech startup with headquarters in San Jose, Costa Rica, and
Houston, Texas. Founded by an experienced and innovative team that
is dedicated to leveraging artificial intelligence for early
disease detection. Recognized with multiple global awards and
renowned partnerships with hospitals and medical device companies,
we proudly introduce VisionAI - our cutting-edge platform designed
to prevent blindness and detect the early onset of diabetes.
Explore how Ainnova is revolutionizing healthcare through advanced
technology and proactive solutions.
About Apollo
Hospitals
Apollo revolutionized healthcare
when Dr. Prathap Reddy opened the first hospital in Chennai in
1983. Today, Apollo is India’s largest integrated healthcare
platform with over 10,000 beds across 73 hospitals, over 6000
pharmacies and over 200 clinics and diagnostic centers, as well as
150 telemedicine centers. It is the world's leading cardiac center
with over 200,000 surgeries and the world’s largest private cancer
care provider. Apollo continues to invest in research to bring the
most cutting-edge technologies, equipment, and treatment protocols
to ensure patients have the best available care in the world.
Apollo’s 100,000 family members are dedicated to bringing you the
best care and leaving the world better than we found it.
About Avant Technologies,
Inc.
Avant Technologies, Inc. is an
emerging technology company developing solutions in artificial
intelligence in healthcare. With a focus on pushing the boundaries
of what is possible in AI and machine learning, Avant serves a
diverse range of industries, driving progress and efficiency
through state-of-the-art technology.
More information about Avant can be
found at https://avanttechnologies.com
You can also follow us on social
media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking
Statements
Certain statements contained in
this press release may constitute “forward-looking
statements.” Forward-looking statements provide current
expectations of future events based on certain assumptions and
include any statement that does not directly relate to any
historical or current fact. Actual results may differ
materially from those indicated by such forward-looking statements
because of various important factors as disclosed in our filings
with the Securities and Exchange Commission located at their
website (http://www.sec.gov). In addition to these factors,
actual future performance, outcomes, and results may differ
materially because of more general factors including (without
limitation) general industry and market conditions and growth
rates, economic conditions, governmental and public policy changes,
the Company’s ability to raise capital on acceptable terms, if at
all, the Company’s successful development of its products and the
integration into its existing products and the commercial
acceptance of the Company’s products. The
forward-looking statements included in this press release represent
the Company's views as of the date of this press release and these
views could change. However, while the Company may elect
to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do
so. These forward-looking statements should not be
relied upon as representing the Company's views as of any date
after the date of the press release.
Contact:
Avant Technologies, Inc.
info@avanttechnologies.com
Avant Technologies (QB) (USOTC:AVAI)
Historical Stock Chart
From Feb 2025 to Mar 2025
Avant Technologies (QB) (USOTC:AVAI)
Historical Stock Chart
From Mar 2024 to Mar 2025
